Damora Therapeutics, Inc.
DMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDamora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. Valued at $1.94B, DMRA is a small-cap name in its sector. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Market Cap
$1.94B
Beta
1.47
P/E (TTM)
—
P/E (Fwd)
-15.15
EPS (TTM)
$-2.78
EPS (Fwd)
$-2.08
ROE
-89.5%
ROA
-14.7%
Cash
$532.9M
Total Debt
$0
Free CF
-$8.7M
52W Change
777.6%
Annual Financials
Cash vs Debt
Damora Therapeutics, Inc. reports $532.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -89.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DMRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.